Disitamabvedotin, also known as Adissib, is a drug used to treat metastatic gastric cancer. It kills cancer cells by binding to the HER2 receptor on the surface of the cancer cells and releasing the Wieck toxin.
1. Indications
Disitamabvedotin is suitable for the treatment of HER2 positive metastatic gastric cancer. HER2 positive metastatic gastric cancer is a subtype of gastric cancer that expresses HER2 receptors. Vidiximab can selectively bind to HER2 receptors, thereby exerting its anti-tumor effects.
2. Efficacy and Function
Vidiximab delivers the toxin to the interior of cancer cells by binding to HER2 receptors on the surface of cancer cells. Vegetatoxin is a cytotoxic molecule that can interfere with the survival and proliferation of cancer cells. Through this mechanism, vediximab can effectively destroy HER2 positive metastatic gastric cancer cells and delay disease progression.
3. Usage and dosage
Vediximab is usually administered via intravenous injection. The recommended dosage is once every 3 weeks, with a dose of 1.25mg/kg each time. A rigorous medical evaluation should be conducted before medication to ensure appropriate dosage and usage. During the medication process, patients should be under the supervision of a doctor to ensure safety and effectiveness.
4. Side effects and precautions
When using vediximab for treatment, there may be some side effects. Common adverse reactions include digestive system symptoms such as fatigue, hair loss, loss of appetite, nausea, vomiting, and diarrhea. In addition, adverse reactions such as neurological, cardiovascular, respiratory, and liver dysfunction may also occur. If the patient experiences serious adverse reactions, they should immediately inform the doctor and stop taking medication.
During the treatment with vediximab, patients need to closely follow the doctor's advice. Precautions include regular medical evaluations, monitoring of treatment efficacy and adverse reactions. In addition, patients should avoid receiving live vaccines as vediximab may reduce their immune response to the vaccine. Meanwhile, pregnant and lactating women should avoid using this medication to prevent adverse effects on the fetus or infant.
